Table 2. Shared differentially expressed genes (FDR-adjusted P-value <.01) between three orthogonal contrasts including the Inactive-Wild Type (IW) baseline group.
| Gene Name* | Log2(Fold) 1 | ||
|---|---|---|---|
| IW-AW2 | IW-AM3 | IW-IM4 | |
| M6prbp1 | -0.55 | -0.92 | 0.47 |
| Pak1 | -0.60 | -1.16 | 1.07 |
| Casq2 | -0.87 | -1.25 | -0.75 |
| Fos | 0.79 | 1.57 | -1.53 |
| Dhrs4 | -0.63 | -0.64 | -0.60 |
| Gm5514 | -1.44 | -1.21 | -1.52 |
| Ddah1 | 0.59 | 2.23 | -2.15 |
| Fabp3 | -0.75 | -0.63 | -0.93 |
| Got1 | -0.62 | -0.55 | -0.44 |
| 2310076L09Rik | -0.87 | -0.72 | -1.04 |
| Mafb | -0.78 | -1.07 | 0.58 |
| EG225594 | -1.64 | -1.55 | 2.22 |
| 4832428D23Rik | -1.20 | -3.91 | 4.48 |
| BDH1 | -1.83 | -1.47 | -2.24 |
| ZMYND11 | 0.85 | 2.10 | -1.63 |
| Gck | 1.17 | 1.48 | -0.70 |
| Esrrb | -1.26 | -1.28 | -1.28 |
| Acaa2 | -0.59 | -0.53 | -0.69 |
| Ankrd2 | -1.18 | -0.92 | -1.59 |
| Actn2 | -0.62 | -0.78 | -0.87 |
| Egr1 | 1.56 | 1.65 | -1.48 |
| Myom3 | -1.13 | -1.08 | -1.93 |
| 9830123M21Rik | 0.69 | 2.52 | -0.49 |
| Rn45s | -0.80 | -1.94 | 1.16 |
| NNT | -0.79 | -0.72 | -0.70 |
| Dgat2 | -0.83 | -0.70 | -0.97 |
| H19 | -0.68 | -0.89 | 0.43 |
| Tbc1d1 | 0.72 | 0.98 | -0.91 |
| IL15 | -1.05 | -1.39 | 1.06 |
| Myh2 | -1.08 | -0.85 | -1.78 |
| COL22A1 | 0.63 | 0.74 | -0.48 |
| ORF63 | 0.85 | 0.93 | -0.75 |
| IDH2 | -0.85 | -0.67 | -0.92 |
| M6prbp1 | -0.55 | -0.92 | 0.47 |
1. When considering two values, A and B, Log2Fold Change = Log2 (B/A). For example, Log2Fold of the contrast AW-IM = log2(IM/AW).
5. IW-AW refers to the inactive wild-type vs. active wild-type contrast group
6. IW-AM refers to the inactive wild-type vs. active myostatin-reduced contrast group
7. IW-IM refers to the jnactive wild-type vs. inactive myostatin-reduced contrast group
*Expanded gene names, listed in alphabetical order: 2310076L09Rik = RIKEN cDNA 2310076L09 gene; 4832428D23Rik = RIKEN cDNA 4832428D23 gene; 9830123M21Rik = RIKEN cDNA 9830123M21 gene; Acaa2 = acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase); Actn2 = actinin alpha 2; Ankrd2 = ankyrin repeat domain 2 (stretch responsive muscle); BDH1 = 3-hydroxybutyrate dehydrogenase, type 1; Casq2 = calsequestrin 2; COL22A1 = collagen, type XXII, alpha 1; Ddah1 = dimethylarginine dimethylaminohydrolase 1; Dgat2 = diacylglycerol O-acyltransferase 2; Dhrs4 = dehydrogenase/reductase (SDR family) member 4; EG225594 = predicted gene 4841; Egr1 = early growth response 1; Esrrb = estrogen related receptor, beta; Fabp3 = fatty acid binding protein 3, muscle and heart; similar to mammary-derived growth inhibitor; Fos = FBJ osteosarcoma oncogene; Gck = glucokinase;Gm5514 = lactate dehydrogenase B; predicted gene 5514; Got1 = similar to Aspartate aminotransferase, cytoplasmic (Transaminase A) (Glutamate oxaloacetate transaminase 1); glutamate oxaloacetate transaminase 1, soluble; H19 = H19 fetal liver mRNA; IDH2 = Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial; IL15 = interleukin 15; M6prbp1 = mannose-6-phosphate receptor binding protein 1; Mafb = v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian); Myh2 = myosin, heavy polypeptide 2, skeletal muscle, adult, myosin, heavy polypeptide 1, skeletal muscle, adult; Myom3 = myomesin family, member 3; Nnt = nicotinamide nucleotide transhydrogenase; ORF63 = open reading frame 63; Pak1 = p21 protein (Cdc42/Rac)-activated kinase 1; Rn45s = RNA, 45S Pre-Ribosomal 5; Tbc1d1 = TBC1 domain family, member 1; similar to TBC1 domain family member 1; ZMYND11 = zinc finger, MYND domain containing 11